HC Wainwright Issues Negative Outlook for TSE:FRX Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Equities researchers at HC Wainwright decreased their FY2024 earnings estimates for Fennec Pharmaceuticals in a report released on Tuesday, December 17th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.18) for the year, down from their previous forecast of $0.11. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.01 EPS and FY2025 earnings at ($0.55) EPS.

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Stock Up 1.0 %

Shares of FRX stock traded up C$0.08 on Thursday, hitting C$8.20. The stock had a trading volume of 357 shares, compared to its average volume of 1,989. The stock’s 50 day moving average is C$7.01 and its 200-day moving average is C$7.68. The firm has a market capitalization of C$224.35 million, a price-to-earnings ratio of 82.00 and a beta of 0.25. Fennec Pharmaceuticals has a 52-week low of C$5.65 and a 52-week high of C$15.43. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02.

Insiders Place Their Bets

In related news, Senior Officer Robert Christopher Andrade acquired 15,816 shares of Fennec Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were purchased at an average cost of C$3.43 per share, for a total transaction of C$54,248.88. 16.20% of the stock is owned by company insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.